Zéna Wimana

980 total citations
23 papers, 641 citations indexed

About

Zéna Wimana is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Epidemiology. According to data from OpenAlex, Zéna Wimana has authored 23 papers receiving a total of 641 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Radiology, Nuclear Medicine and Imaging, 14 papers in Oncology and 8 papers in Epidemiology. Recurrent topics in Zéna Wimana's work include Radiopharmaceutical Chemistry and Applications (13 papers), Neuroendocrine Tumor Research Advances (8 papers) and HER2/EGFR in Cancer Research (8 papers). Zéna Wimana is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (13 papers), Neuroendocrine Tumor Research Advances (8 papers) and HER2/EGFR in Cancer Research (8 papers). Zéna Wimana collaborates with scholars based in Belgium, Netherlands and United States. Zéna Wimana's co-authors include Patrick Flamen, Géraldine Gebhart, Thomas Guiot, Camilo Garcia, Elisabeth G.E. de Vries, Wim J.G. Oyen, Sigrid Stroobants, Adrienne H. Brouwers, Manon Huizing and C. Willemien Menke‐van der Houven van Oordt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Zéna Wimana

20 papers receiving 638 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zéna Wimana Belgium	11	458	338	183	88	57	23	641
E Barendswaard United States	10	336 0.7×	177 0.5×	150 0.8×	123 1.4×	65 1.1×	11	626
Dan Sandberg Sweden	7	578 1.3×	358 1.1×	125 0.7×	158 1.8×	26 0.5×	13	689
Michael Garkavij Sweden	10	546 1.2×	314 0.9×	351 1.9×	51 0.6×	95 1.7×	23	727
Bianca A.W. Hoeben Netherlands	15	361 0.8×	135 0.4×	201 1.1×	107 1.2×	45 0.8×	29	651
Kirk Trisler United States	9	383 0.8×	160 0.5×	225 1.2×	106 1.2×	20 0.4×	13	576
Maria Liza Lindenberg United States	16	384 0.8×	136 0.4×	429 2.3×	137 1.6×	18 0.3×	35	742
Alan J. Green United Kingdom	10	506 1.1×	120 0.4×	143 0.8×	90 1.0×	83 1.5×	15	632
Stephanie Robu Germany	10	385 0.8×	310 0.9×	411 2.2×	69 0.8×	33 0.6×	14	777
Harukaze Yamamoto Japan	12	285 0.6×	548 1.6×	182 1.0×	127 1.4×	29 0.5×	25	794
Quan‐Sing Ng Singapore	13	237 0.5×	256 0.8×	251 1.4×	151 1.7×	17 0.3×	17	770

Countries citing papers authored by Zéna Wimana

Since Specialization

Citations

This map shows the geographic impact of Zéna Wimana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zéna Wimana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zéna Wimana more than expected).

Fields of papers citing papers by Zéna Wimana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zéna Wimana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zéna Wimana. The network helps show where Zéna Wimana may publish in the future.

Co-authorship network of co-authors of Zéna Wimana

This figure shows the co-authorship network connecting the top 25 collaborators of Zéna Wimana. A scholar is included among the top collaborators of Zéna Wimana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zéna Wimana. Zéna Wimana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Karfis, Ioannis, et al.. (2025). The SCARLET trial: a prospective phase II study of somatostatin receptor imaging for potential radiotheranostic application in patients with relapsing and refractory multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging. 53(3). 1521–1531.

Marta, Guilherme Nader, et al.. (2025). PSMA-targeted PET imaging in patients with metastatic triple-negative breast cancer: results of the prospective PRISMA trial. European Journal of Nuclear Medicine and Molecular Imaging. 53(5). 3152–3161.

Artigas, Carlos, Hugo Levillain, Lieveke Ameye, et al.. (2024). 177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Clinical Nuclear Medicine. 49(9). 847–853. 5 indexed citations

Rediti, Mattia, Danai Fimereli, Zéna Wimana, et al.. (2024). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical Cancer Research. 31(1). 110–121. 3 indexed citations

Kristanto, Paulus, Bruno Vanderlinden, Zéna Wimana, et al.. (2024). Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. EJNMMI Research. 14(1). 110–110. 2 indexed citations

Vries, Elisabeth G.E. de, Thomas Guiot, Zéna Wimana, et al.. (2024). Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). npj Breast Cancer. 10(1). 4–4. 21 indexed citations

Stamatopoulos, Basile, Nicolas Sirtaine, Pieter Demetter, et al.. (2023). Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Cancers. 15(8). 2332–2332. 2 indexed citations

Penninckx, Sébastien, et al.. (2022). Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy. International Journal of Molecular Sciences. 23(20). 12369–12369. 10 indexed citations

Ghanem, Ghanem E., et al.. (2021). Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nuclear Medicine and Biology. 96-97. 68–79. 6 indexed citations

10.

Artigas, Carlos, Patrick Flamen, Hugo Levillain, et al.. (2019). 68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. World Journal of Urology. 37(8). 1535–1542. 22 indexed citations

11.

Vanderlinden, Bruno, Ioannis Karfis, Thomas Guiot, et al.. (2018). A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours. Physica Medica. 56. 41–49. 42 indexed citations

12.

Bartelink, Imke H., Ella F. Jones, Sheerin Shahidi-Latham, et al.. (2018). Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. Clinical Pharmacology & Therapeutics. 106(1). 148–163. 63 indexed citations

13.

Vanderlinden, Bruno, Ioannis Karfis, Thomas Guiot, et al.. (2017). Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy. EJNMMI Physics. 4(1). 7–7. 22 indexed citations

14.

Wimana, Zéna, Géraldine Gebhart, Thomas Guiot, et al.. (2017). N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget. 8(34). 56185–56198. 13 indexed citations

15.

Fastrez, Maxime, Carlos Artigas, Nicolas Sirtaine, et al.. (2017). Value of the 68Ga-DOTATATE PET-CT in the diagnosis of endometriosis. A pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 212. 69–74. 10 indexed citations

16.

Gebhart, Géraldine, Patrick Flamen, Elisabeth G.E. de Vries, Komal Jhaveri, & Zéna Wimana. (2016). Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. Journal of Nuclear Medicine. 57(Supplement 1). 81S–88S. 40 indexed citations

17.

Artigas, Carlos, Camilo Garcia, Zéna Wimana, et al.. (2015). Paget bone disease demonstrated on 68Ga-PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 43(1). 195–196. 82 indexed citations

18.

Gebhart, Géraldine, Laetitia E. Lamberts, Zéna Wimana, et al.. (2015). Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Annals of Oncology. 27(4). 619–624. 265 indexed citations

19.

Wimana, Zéna, Géraldine Gebhart, Thomas Guiot, et al.. (2015). Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [89Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model. Molecular Imaging and Biology. 17(5). 697–703. 11 indexed citations

20.

Gebhart, Géraldine, Laetitia E. Lamberts, Camilo Garcia, et al.. (2014). PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. Journal of Clinical Oncology. 32(15_suppl). 11001–11001. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact